TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of “Moderate Buy” from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has received an average recommendation of “Moderate Buy” from the six analysts that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $50.00.

A number of equities research analysts have recently issued reports on TGTX shares. JPMorgan Chase & Co. reduced their price target on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research note on Monday, February 2nd. Cantor Fitzgerald reissued an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. The Goldman Sachs Group upped their price objective on TG Therapeutics from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Thursday, January 15th. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th.

Insider Buying and Selling

In related news, Director Yann Echelard sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total transaction of $162,850.00. Following the transaction, the director owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This trade represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 10.64% of the company’s stock.

Institutional Trading of TG Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Johnson Investment Counsel Inc. acquired a new position in TG Therapeutics during the fourth quarter worth about $245,000. Segall Bryant & Hamill LLC raised its holdings in shares of TG Therapeutics by 147.3% in the fourth quarter. Segall Bryant & Hamill LLC now owns 192,454 shares of the biopharmaceutical company’s stock worth $5,737,000 after acquiring an additional 114,621 shares during the last quarter. Bridgewater Associates LP boosted its stake in shares of TG Therapeutics by 37.3% during the 4th quarter. Bridgewater Associates LP now owns 469,855 shares of the biopharmaceutical company’s stock worth $14,006,000 after purchasing an additional 127,706 shares during the last quarter. Stifel Financial Corp grew its stake in TG Therapeutics by 209.2% in the 4th quarter. Stifel Financial Corp now owns 37,469 shares of the biopharmaceutical company’s stock worth $1,117,000 after acquiring an additional 25,349 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 16.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 3,147 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 454 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Trading Up 0.3%

TGTX opened at $28.50 on Friday. The stock has a market capitalization of $4.52 billion, a PE ratio of 10.25 and a beta of 1.85. TG Therapeutics has a one year low of $25.28 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The business’s 50 day moving average price is $30.09 and its 200 day moving average price is $31.49.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.